My Shares and Shares ISA has two roles. The primary is to construct up my wealth whereas I’m working. The second is to launch earnings after I retire.

I’ve bought some whizzy development shares in there, together with cosmetics maker Warpaint and outsourcing agency Costain Group. However I’ve additionally bought a heap of income-paying FTSE 100 blue-chips, and I’m pinning most of my hopes on them.

At present, they’re largely neglected by buyers, who would relatively trip with the Magnificent Seven US tech heroes. My FTSE faves could also be just a little boring however they’re lovely in their very own manner.

FTSE 100 beauties

I want to purchase shares once they’re out of favour, relatively than using excessive. That enables me to choose them up at a reduced price, and safe an elevated yield.

My view is that UK dividend shares would swing again into favour as soon as rates of interest peak and financial savings charges and bond yields fell. That situation has taken longer to pan out than I hoped, however it ought to occur in some unspecified time in the future. And when it does, I hope to bag some share price development on prime of my dividend earnings.

My favorite less-than-magnificent seven blue-chips are GSK (LSE: GSK), Lloyds Banking Group, Authorized & Common Group, M&G, Phoenix Group Holdings, Unilever and Taylor Wimpey.

They’re boring in comparison with, say, Nvidia and Tesla, however do provide the occasional flash of pleasure.

The Taylor Wimpey share price is up 33.79% during the last yr. And it nonetheless has a trailing yield of 6.1%. Lloyds is up 29.11% and yields 4.64% (that’s forecast to hit 5.5%).

The Phoenix share price has been boring for yonks however it does yield 9.92%. It was a lovely day when the final dividend hit my portfolio.

Dividend earnings heroes

GSK‘s been interesting, but in the wrong way. I bought its shares in March and again in June, thinking it was due a share price recovery. So far, I’m down 10.73%. These are early days however I anticipated higher. Over one yr, they’re up 8.61%.

Pharmaceutical shares are considered defensive however may also be risky. Bringing new remedies to market is a tortuous course of, with potential failure at each flip. Even the blockbuster successes will come off patent in some unspecified time in the future, hitting gross sales, so thrilling new remedies must be discovered.

Plus there’s the specter of litigation. GSK’s heartburn remedy Zantac has been accused of inflicting most cancers. Information that instances would go to trial within the US knocked 10% off the GSK share price in a single day. It has but to recuperate and possibly received’t till the trial is completed. And perhaps not even then if the decision goes the flawed manner.

I’ll stick it out although. Over the longer run, I believe GSK shares will come good, and right this moment’s so-so 3.89% yield will lastly recuperate.

These seven oh-so-boring shares will sit in my Shares and Shares ISA for years doing their factor. Once I retire, I anticipate them to ship a stream of tax-free earnings, and perhaps some capital development too. Lovely.